An observational study in Acute Myocardial Infarction, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, 2 of them phase 3. Myocardial Infarction · Assistance Publique - Hôpitaux de Paris.
Among the 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2019, is one of 4 observational ones, and was the 12th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →4 of the 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 1,136 across the 12 interventional studies, 2,125 across the 4 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05577988Phase 3Assistance Publique - Hôpitaux de ParisAssessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome | 2027-06 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Myocardial Infarction by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Over the last two decades, considerable progress has been made in the management of Acute Myocardial Infarction (AMI), both in the acute phase and in monitoring beyond the hospital phase. Nevertheless, the evolution of care practices and their impact on the mid- and long-term prognosis of patients admitted to the intensive care unit for acute myocardial infarction remain relatively little studied exhaustively.
The aim of this study is to assess the profile of AMI patients, their management and follow-up in order to evaluate the relationship between these factors and outcomes.
The FRENCHIE registry is a French multicenter prospective observational study. All the eligible consecutive patients admitted within 48 hours after symptom onset in a cardiac ICU for an acute myocardial infarction.
This hospital registry will be linked to the national databases, in order to collect follow-up clinical outcomes and health care consumption.
Consecutive eligible (cf eligibility criteria) patients admitted in one of the Intensive Coronary Units participating to the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
As it is an observational study, no intervention is planned. However, nested clinical interventional trials are planned for which a specific registration will be done
In-hospital mortality
In-hospital mortality
Time frame: Through the end of initial hospitalization, an average of 5 days
In-hospital outcomes
To measure the in-hospital major cardiovascular events : recurrence of AMI, myocardial revascularization, stroke
Time frame: Through the end of initial hospitalization, an average of 5 days
Lipopretein 1 evolution
To evaluate plasma concentrations of Lpa and its dynamic pattern during hospital index and 3-9 months following hospitalization.
Time frame: 9 months after the end of initial hospitalization
Cardiovascular outcomes during follow-up
All cause death and Cardiovascular events including non fatal Myocardial Infarction, non fatal stroke, revascularization, hospitalization for other cardiovascular causes including Bleeding leading to hospitalization
Time frame: Up to 20 years
Non cardiovascular outcomes during follow-up
All cause death and Non-cardiovascular events leading to to hospitalizations
Time frame: Up to 20 years
Relationship between patients profile and mortality and cardiovascular morbidity outcomes according to management
All cause death and cardiovascular events including non fatal MI, non fatal stroke, revascularization, hospitalization for other cardiovascular causes including Bleeding leading to hospitalization according to patient's management
Time frame: Up to 20 years
Relationship between patients profile and mortality and non-cardiovascular morbidity outcomes according to management
All cause death and Non-cardiovascular events leading to to hospitalizations according to patient's management
Time frame: Up to 20 years
Oral comorbidities
Prevalence of oral pathology and its relationship with early, mid, and long-term prognosis and outcomes
Time frame: Up to 20 years
Sleep disordered breathing comorbidities
To assess the prevalence of sleep disordered breathing comorbidities and the relationship with early, mid, and long-term prognosis and outcomes
Time frame: Up to 20 years
Evaluate the path of care combined with patient care practices following an acute myocardial infarction
Evaluate the path of care and patient care practices following an acute myocardial infarction : Reimbursed or prescribed treatments, combined with number of visits, biological and tests performed
Time frame: Up to 20 years
Evaluate the relevance of European Society of Cardiology (ESC), American Heart Association/American College of Cardiology (AHA / ACC) guidelines regarding management of AMI patients
Evaluate the relevance of ESC, AHA/ACC guidelines regarding management of AMI patients
Time frame: Up to 20 years
Cost-utility: incremental (or decremental) cost-utility ratio during follow-up
Medical care costs for the index hospitalization and during follow-up period are assessed using a combination of resource-based and event-based methods. In-hospital resource utilization are based on diagnosis and procedural codes and length of stay.
Time frame: Up to 20 years
Plan to share: Undecided
Started Mar 2019 (actual). Primary completion is estimated for Mar 2029, 120 months after the start.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 120 months is above that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →